Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.

Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, Narwal R, Petrone M, Roberts J, Brown L, Cusdin F, Dosanjh B, Lloyd C, Dobson C, Gurrell I, Fraser G, McFarlane M, Rockenstein E, Spencer B, Masliah E, Spillantini MG, Tan K, Billinton A, Vaughan T, Chessell I, Perkinton MS.

Neurobiol Dis. 2019 Dec;132:104582. doi: 10.1016/j.nbd.2019.104582. Epub 2019 Aug 21.

PMID:
31445162
2.

Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.

Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA.

Alzheimers Dement. 2019 Sep;15(9):1133-1148. doi: 10.1016/j.jalz.2019.02.002. Epub 2019 Aug 1.

PMID:
31378574
3.

A cullin-RING ubiquitin ligase targets exogenous α-synuclein and inhibits Lewy body-like pathology.

Gerez JA, Prymaczok NC, Rockenstein E, Herrmann US, Schwarz P, Adame A, Enchev RI, Courtheoux T, Boersema PJ, Riek R, Peter M, Aguzzi A, Masliah E, Picotti P.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaau6722. doi: 10.1126/scitranslmed.aau6722.

PMID:
31167929
4.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
5.

The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles.

Snow AD, Castillo GM, Nguyen BP, Choi PY, Cummings JA, Cam J, Hu Q, Lake T, Pan W, Kastin AJ, Kirschner DA, Wood SG, Rockenstein E, Masliah E, Lorimer S, Tanzi RE, Larsen L.

Sci Rep. 2019 Feb 6;9(1):561. doi: 10.1038/s41598-019-38645-0.

6.

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies.

Hassen GW, Kesner L, Stracher A, Shulman A, Rockenstein E, Mante M, Adame A, Overk C, Rissman RA, Masliah E.

Sci Rep. 2018 Dec 27;8(1):18083. doi: 10.1038/s41598-018-35729-1.

7.

Neuronal Exosome-Derived Human Tau is Toxic to Recipient Mouse Neurons in vivo.

Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN, Mishra P, Rissman RA, Yuan SH.

J Alzheimers Dis. 2019;67(2):541-553. doi: 10.3233/JAD-180776.

PMID:
30584143
8.

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.

Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D.

Sci Rep. 2018 Nov 1;8(1):16165. doi: 10.1038/s41598-018-34490-9.

9.

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.

Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ.

Nat Commun. 2018 Aug 27;9(1):3465. doi: 10.1038/s41467-018-05958-z.

10.

T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation.

Chen XQ, Fang F, Florio JB, Rockenstein E, Masliah E, Mobley WC, Rissman RA, Wu C.

Traffic. 2018 Nov;19(11):840-853. doi: 10.1111/tra.12610. Epub 2018 Sep 12.

11.

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.

Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E.

Mol Neurodegener. 2018 Aug 9;13(1):43. doi: 10.1186/s13024-018-0276-2.

12.

Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Spencer B, Brüschweiler S, Sealey-Cardona M, Rockenstein E, Adame A, Florio J, Mante M, Trinh I, Rissman RA, Konrat R, Masliah E.

Acta Neuropathol. 2018 Jul;136(1):69-87. doi: 10.1007/s00401-018-1869-0. Epub 2018 Jun 14.

13.

Doublecortin expression in CD8+ T-cells and microglia at sites of amyloid-β plaques: A potential role in shaping plaque pathology?

Unger MS, Marschallinger J, Kaindl J, Klein B, Johnson M, Khundakar AA, Roßner S, Heneka MT, Couillard-Despres S, Rockenstein E, Masliah E, Attems J, Aigner L.

Alzheimers Dement. 2018 Aug;14(8):1022-1037. doi: 10.1016/j.jalz.2018.02.017. Epub 2018 Apr 7.

14.

Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.

Arner A, Rockenstein E, Mante M, Florio J, Masliah D, Salehi B, Adame A, Overk C, Masliah E, Rissman RA.

J Alzheimers Dis. 2018;61(3):1201-1219. doi: 10.3233/JAD-170388.

15.

Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.

Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, Adame A, Trinh I, Kim C, Overk C, Masliah E, Rissman RA.

J Neurosci. 2018 Jan 24;38(4):1000-1014. doi: 10.1523/JNEUROSCI.1170-17.2017. Epub 2017 Dec 15.

16.

Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype.

Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K, Bergmann A, Rockenstein E, Adame A, Marxreiter F, Mollenhauer B, Galasko D, Buzás EI, Schlötzer-Schrehardt U, Marcus K, Xiang W, Lie DC, Vekrellis K, Masliah E, Winkler J, Klucken J.

Autophagy. 2018;14(1):98-119. doi: 10.1080/15548627.2017.1395992. Epub 2018 Jan 15.

17.

Oligomer-prone E57K-mutant alpha-synuclein exacerbates integration deficit of adult hippocampal newborn neurons in transgenic mice.

Regensburger M, Schreglmann SR, Stoll S, Rockenstein E, Loskarn S, Xiang W, Masliah E, Winner B.

Brain Struct Funct. 2018 Apr;223(3):1357-1368. doi: 10.1007/s00429-017-1561-5. Epub 2017 Nov 9.

18.

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy.

Valera E, Spencer B, Mott J, Trejo M, Adame A, Mante M, Rockenstein E, Troncoso JC, Beach TG, Masliah E, Desplats P.

Front Mol Neurosci. 2017 Oct 17;10:329. doi: 10.3389/fnmol.2017.00329. eCollection 2017.

19.

Multiple system atrophy: experimental models and reality.

Overk C, Rockenstein E, Valera E, Stefanova N, Wenning G, Masliah E.

Acta Neuropathol. 2018 Jan;135(1):33-47. doi: 10.1007/s00401-017-1772-0. Epub 2017 Oct 20. Review.

20.

Increased BACE1 activity inhibits peripheral nerve regeneration after injury.

Tallon C, Rockenstein E, Masliah E, Farah MH.

Neurobiol Dis. 2017 Oct;106:147-157. doi: 10.1016/j.nbd.2017.07.003. Epub 2017 Jul 5.

PMID:
28687442
21.

Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease.

Fang F, Yang W, Florio JB, Rockenstein E, Spencer B, Orain XM, Dong SX, Li H, Chen X, Sung K, Rissman RA, Masliah E, Ding J, Wu C.

Sci Rep. 2017 Jun 20;7(1):3868. doi: 10.1038/s41598-017-04232-4.

22.

Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Reilly P, Winston CN, Baron KR, Trejo M, Rockenstein EM, Akers JC, Kfoury N, Diamond M, Masliah E, Rissman RA, Yuan SH.

Neurobiol Dis. 2017 Oct;106:222-234. doi: 10.1016/j.nbd.2017.06.005. Epub 2017 Jun 10.

23.

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology.

Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA.

Acta Neuropathol Commun. 2017 Jun 9;5(1):46. doi: 10.1186/s40478-017-0445-5.

24.

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

El-Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2017 Aug;104:85-96. doi: 10.1016/j.nbd.2017.05.002. Epub 2017 May 2.

25.

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.

Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B.

BMC Neurosci. 2017 Jan 31;18(1):22. doi: 10.1186/s12868-017-0341-8.

26.

Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo.

Guimarães-Camboa N, Cattaneo P, Sun Y, Moore-Morris T, Gu Y, Dalton ND, Rockenstein E, Masliah E, Peterson KL, Stallcup WB, Chen J, Evans SM.

Cell Stem Cell. 2017 Mar 2;20(3):345-359.e5. doi: 10.1016/j.stem.2016.12.006. Epub 2017 Jan 19.

27.

The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Fields JA, Metcalf J, Overk C, Adame A, Spencer B, Wrasidlo W, Florio J, Rockenstein E, He JJ, Masliah E.

J Neurovirol. 2017 Apr;23(2):290-303. doi: 10.1007/s13365-016-0502-z. Epub 2017 Jan 19.

28.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

29.

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.

Valera E, Spencer B, Fields JA, Trinh I, Adame A, Mante M, Rockenstein E, Desplats P, Masliah E.

Acta Neuropathol Commun. 2017 Jan 5;5(1):2. doi: 10.1186/s40478-016-0409-1.

30.

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet MF, Meier D, Moessler H, Konrat R, Masliah E.

Brain. 2016 Dec;139(Pt 12):3217-3236. Epub 2016 Sep 27.

31.

α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.

Spencer B, Williams S, Rockenstein E, Valera E, Xin W, Mante M, Florio J, Adame A, Masliah E, Sierks MR.

Ann Clin Transl Neurol. 2016 Jun 16;3(8):588-606. doi: 10.1002/acn3.321. eCollection 2016 Aug.

32.

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.

Xu J, de Winter F, Farrokhi C, Rockenstein E, Mante M, Adame A, Cook J, Jin X, Masliah E, Lee KF.

Sci Rep. 2016 Aug 25;6:31692. doi: 10.1038/srep31692.

33.

Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, Mante M, Adame A, Florio J, Rockenstein E, Masliah E.

J Neurosci. 2016 Jul 27;36(30):7971-84. doi: 10.1523/JNEUROSCI.0775-16.2016.

34.

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.

Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA.

Alzheimers Dement (Amst). 2016 May 7;3:63-72. doi: 10.1016/j.dadm.2016.04.001. eCollection 2016.

35.

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.

Price DL, Rockenstein E, Mante M, Adame A, Overk C, Spencer B, Duong-Polk KX, Bonhaus D, Lindsey J, Masliah E.

Sci Rep. 2016 Jul 8;6:29523. doi: 10.1038/srep29523.

36.

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.

Fields JA, Overk C, Adame A, Florio J, Mante M, Pineda A, Desplats P, Rockenstein E, Achim C, Masliah E.

J Neuroinflammation. 2016 May 24;13(1):120. doi: 10.1186/s12974-016-0585-8.

37.

Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.

Rockenstein E, Clarke J, Viel C, Panarello N, Treleaven CM, Kim C, Spencer B, Adame A, Park H, Dodge JC, Cheng SH, Shihabuddin LS, Masliah E, Sardi SP.

Hum Mol Genet. 2016 Jul 1;25(13):2645-2660. Epub 2016 Apr 28.

38.

The HIV Protein gp120 Alters Mitochondrial Dynamics in Neurons.

Avdoshina V, Fields JA, Castellano P, Dedoni S, Palchik G, Trejo M, Adame A, Rockenstein E, Eugenin E, Masliah E, Mocchetti I.

Neurotox Res. 2016 May;29(4):583-593. doi: 10.1007/s12640-016-9608-6. Epub 2016 Mar 2.

39.

Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.

Fares MB, Maco B, Oueslati A, Rockenstein E, Ninkina N, Buchman VL, Masliah E, Lashuel HA.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E912-21. doi: 10.1073/pnas.1512876113. Epub 2016 Feb 2.

40.

α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.

Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, Adame A, Lee SJ, Desplats P, Masliah E.

Hum Mol Genet. 2016 Mar 15;25(6):1100-15. doi: 10.1093/hmg/ddv633. Epub 2016 Jan 5.

41.

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease.

Kim C, Ojo-Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, Wrasidlo W, Adame A, Nchekwube E, Oyemade O, Okogun J, Chan M, Cottam H, Masliah E.

J Neuroinflammation. 2015 Dec 18;12:236. doi: 10.1186/s12974-015-0455-9.

42.

Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.

Spencer B, Potkar R, Metcalf J, Thrin I, Adame A, Rockenstein E, Masliah E.

J Biol Chem. 2016 Jan 22;291(4):1905-20. doi: 10.1074/jbc.M115.678185. Epub 2015 Nov 30.

43.

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.

Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

BMC Neurosci. 2015 Nov 26;16:85. doi: 10.1186/s12868-015-0218-7.

44.

HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders.

Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, Trejo M, Adame A, Spencer B, Rockenstein E, Murphy AN, Ellis RJ, Letendre S, Grant I, Masliah E.

Neurobiol Dis. 2016 Feb;86:154-69. doi: 10.1016/j.nbd.2015.11.015. Epub 2015 Nov 22.

45.

Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy.

Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ, Masliah E.

Cell Rep. 2015 Oct 27;13(4):771-782. doi: 10.1016/j.celrep.2015.09.044. Epub 2015 Oct 17.

46.

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.

Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E.

Mol Neurodegener. 2015 Sep 23;10:48. doi: 10.1186/s13024-015-0043-6.

47.

Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.

Overk CR, Rockenstein E, Florio J, Cheng Q, Masliah E.

Neuroscience. 2015 Dec 3;310:549-60. doi: 10.1016/j.neuroscience.2015.08.068. Epub 2015 Sep 2.

48.

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang YW, St George-Hyslop P, Masliah E, Fraser P, Xu H.

Neuron. 2015 Sep 2;87(5):963-75. doi: 10.1016/j.neuron.2015.08.020.

49.

Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

Stem Cell Res. 2015 Jul;15(1):54-67. doi: 10.1016/j.scr.2015.04.008. Epub 2015 May 9.

50.

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

Valera E, Mante M, Anderson S, Rockenstein E, Masliah E.

J Neuroinflammation. 2015 May 14;12:93. doi: 10.1186/s12974-015-0320-x.

Supplemental Content

Loading ...
Support Center